We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
-3.39%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$9.1B
AUM Growth
-$787M
Cap. Flow
+$233M
Cap. Flow %
2.56%
Top 10 Hldgs %
30.12%
Holding
189
New
31
Increased
28
Reduced
27
Closed
17

Top Buys

Rank Stock Value
1
IVVD icon
Invivyd
IVVD
+$200M
2
ZBH icon
Zimmer Biomet
ZBH
+$100M
3
BIIB icon
Biogen
BIIB
+$54.7M
4
HCA icon
HCA Healthcare
HCA
+$47.4M
5
MREO
Mereo BioPharma
MREO
+$45.7M

Top Sells

Rank Stock Value
1
AUPH icon
Aurinia Pharmaceuticals
AUPH
+$78.7M
2
ASND icon
Ascendis Pharma A/S
ASND
+$58.9M
3
NTRA icon
Natera
NTRA
+$55.6M
4
ELV icon
Elevance Health
ELV
+$48.9M
5
BSX icon
Boston Scientific
BSX
+$48.1M

Sector Composition

Rank Sector Weight
1 Healthcare 95.35%
2 Technology 0.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KDNY
101
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$18.1M 0.2%
1,420,637
+86,836
+7% +$1.14M
ELVN icon
102
Enliven Therapeutics
ELVN
$3.78B
$17.9M 0.2%
1,096,642
+416,666
+61% +$8.66M
HUMA icon
103
Humacyte
HUMA
$170M
$17.4M 0.19%
+1,500,000
New +$17.2M
NRIX icon
104
Nurix Therapeutics
NRIX
$2.46B
$17.3M 0.19%
578,583
+278,583
+93% +$8.6M
FLXN
105
DELISTED
Flexion Therapeutics, Inc.
FLXN
$16.9M 0.19%
2,769,383
– –
RXST icon
106
RxSight
RXST
$252M
$15.8M 0.17%
+1,250,000
New +$17.2M
LUNG icon
107
Pulmonx
LUNG
$53.6M
$15.7M 0.17%
435,000
+310,000
+248% +$12.2M
BLU
108
DELISTED
BELLUS Health Inc.
BLU
$15M 0.16%
2,454,800
-1,500,000
-38% -$5.69M
MIST icon
109
Milestone Pharmaceuticals
MIST
$129M
$14.8M 0.16%
2,583,821
– –
DMRA
110
Damora Therapeutics, Inc. Ordinary Shares
DMRA
$1.81B
$14.7M 0.16%
163,637
– –
DICE
111
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
$14.4M 0.16%
+440,000
New +$15M
CALC icon
112
CalciMedica
CALC
$11.9M
$13.8M 0.15%
297,382
– –
DNTH icon
113
Dianthus Therapeutics
DNTH
$5.62B
$13.8M 0.15%
118,310
-8,800
-7% -$1.03M
CVRX icon
114
CVRx
CVRX
$133M
$13.2M 0.15%
799,861
+399,861
+100% +$7.67M
VOR icon
115
Vor Biopharma
VOR
$1.06B
$13.1M 0.14%
41,667
– –
ACHL
116
DELISTED
Achilles Therapeutics
ACHL
$12.3M 0.14%
1,584,845
– –
AMGN icon
117
Amgen
AMGN
$213B
$12.1M 0.13%
57,100
– –
ACRS icon
118
Aclaris Therapeutics
ACRS
$722M
$11.7M 0.13%
651,783
+289,783
+80% +$4.65M
JBIO
119
Jade Biosciences
JBIO
$1.19B
$11.2M 0.12%
15,306
– –
GYRE icon
120
Gyre Therapeutics
GYRE
$659M
$11.1M 0.12%
361,547
+79,067
+28% +$2.6M
NMTR
121
DELISTED
9 Meters Biopharma
NMTR
$11.1M 0.12%
428,299
– –
ALXO icon
122
ALX Oncology
ALXO
$265M
$11.1M 0.12%
150,000
– –
EVH icon
123
Evolent Health
EVH
$403M
$10.7M 0.12%
+345,000
New +$8.28M
IPSC icon
124
Century Therapeutics
IPSC
$361M
$10.2M 0.11%
407,047
– –
WHWK
125
Whitehawk Therapeutics
WHWK
$177M
$10.2M 0.11%
346,262
-1
-0% -$30
3 4
5
6 7

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q3 2021 Portfolio in Review

As of Q3 2021, OrbiMed held 189 positions worth $9.1B, down 8% from $9.89B the previous quarter. Its ten largest holdings account for 30% of the portfolio.

OrbiMed's Q3 2021 filing shows 31 new, 28 increased, 27 reduced and 17 closed positions. Its largest new stake was Invivyd: 5,383,500 shares worth $227M. The largest sale was Aurinia Pharmaceuticals, an estimated $78.7M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 95% a quarter earlier, followed by Technology.

  • OrbiMed's largest Q3 2021 buy was Invivyd: 5,383,500 shares worth $227M.
  • OrbiMed added most to Biogen in Q3 2021, an estimated $54.7M increase.
  • OrbiMed's biggest Q3 2021 reduction was Natera, cutting an estimated $55.6M.
  • OrbiMed fully exited Aurinia Pharmaceuticals in Q3 2021, selling an estimated $78.7M.
  • OrbiMed's ten largest holdings make up 30% of its $9.1B portfolio in Q3 2021.
  • OrbiMed opened 31 new positions and closed 17 in Q3 2021.
  • OrbiMed's portfolio value fell 8% quarter-over-quarter to $9.1B.

Based on OrbiMed's 13F filing for Q3 2021, filed 15 Nov 2021.